News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data on GI Dynamics’ EndoBarrier® Therapy Presented at the American Diabetes Association 72nd Scientific Sessions


6/11/2012 10:13:06 AM

LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID), a company pioneering the development of effective non-surgical approaches for treating type 2 diabetes and obesity, announced today that data from a previously reported multi-center, randomized, controlled trial evaluating EndoBarrier® Therapy in obese patients with type 2 diabetes were highlighted on Saturday, June 9, 2012, at the American Diabetes Association's (ADA) 72nd Scientific Sessions in Philadelphia.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES